First-line treatment
Showing 1 - 25 of >10,000
Can Digitally Delivered First-line Osteoarthritis Treatment
Recruiting
- Health Services Accessibility
- +2 more
- Digitally delivered first-line treatment for osteoarthritis
- Face-to-face first-line treatment for osteoarthritis
-
Malmö, SwedenJoint Academy
Nov 20, 2023
Tislelizumab Combined With Chemotherapy in First-line Treatment
Active, not recruiting
- Tislelizumab
- +3 more
-
Beijing, ChinaCancer Institute and Hospital, Chinese Academy of Medical Scienc
Sep 6, 2023
Advanced Mucosal Melanoma Trial (Envafolimab combined with recombinant human endostatin and first-line chemo)
Not yet recruiting
- Advanced Mucosal Melanoma
- Envafolimab combined with recombinant human endostatin and first-line chemotherapy
- (no location specified)
Sep 15, 2023
Hodgkin Lymphoma Trial in Cologne (Pembrolizumab)
Not yet recruiting
- Hodgkin Lymphoma
-
Cologne, Germany1st Department of Medicine, Cologne University Hospital
Sep 19, 2023
Tislelizumab, Bevacizumab, Oxaliplatin Trial in Beijing (Tislelizumab+Bevacizumab+Oxaliplatin+Capecitabine)
Recruiting
- Tislelizumab
- +7 more
-
Beijing, ChinaLin Yang
Jul 21, 2023
Nasopharyngeal Carcinoma Trial in Zhongshan (Anrotinib plus Tirelizumab)
Recruiting
- Nasopharyngeal Carcinoma
- Anrotinib plus Tirelizumab
-
Zhongshan, Guangdong, ChinaZhongshan City People's Hospital
Jul 31, 2023
Colorectal Carcinoma Trial (Fruquintinib?Capecitabine Tablets)
Not yet recruiting
- Colorectal Carcinoma
- Fruquintinib、Capecitabine Tablets
- (no location specified)
Oct 30, 2023
First-line Maintenance Treatment of PTCL With Chidamide.
Recruiting
- PTCL
-
Nanjing, Jiangsu, ChinaHematological Department, People's Hospital of Jiangsu Province
Jul 23, 2023
Cancer Of Pancreas Trial (Analyze of GemCore status)
Not yet recruiting
- Cancer Of Pancreas
- Analyze of GemCore status
- (no location specified)
Sep 19, 2023
NSCLC Trial in Shanghai (Toripalimab, Cryoablation)
Not yet recruiting
- Non-small Cell Lung Cancer
- Toripalimab
- Cryoablation
-
Shanghai, Shanghai, ChinaShanghai Chest Hospital
Nov 7, 2023
First-line Treatment of Non-clear Renal Cell Carcinoma Trial (Fruquintinib combined with Serplulimab)
Not yet recruiting
- First-line Treatment of Non-clear Renal Cell Carcinoma
- Fruquintinib combined with Serplulimab
- (no location specified)
Apr 16, 2023
Colorectal Cancer Trial in Tai'an (Tas-102(Suyuan) combined with bevacizumab)
Not yet recruiting
- Colorectal Cancer
- Tas-102(Suyuan) combined with bevacizumab
-
Tai'an, Shandong, ChinaThe Second Affiliated Hospital of Shandong First Medical Univers
Oct 14, 2023
Hepatocellular Carcinoma Trial in Beijing (Lenvatinib Plus Tislelizumab, Transarterial Chemoembolization(TACE))
Recruiting
- Hepatocellular Carcinoma
- Lenvatinib Plus Tislelizumab
- Transarterial Chemoembolization(TACE)
-
Beijing, Beijing, ChinaNan Zhang
Apr 22, 2023
Gastrointestinal Neuroendocrine Carcinoma Trial in Beijing (Durvalumab and Chemotherapy(oxaliplatin and capecitabine))
Recruiting
- Gastrointestinal Neuroendocrine Carcinoma
- Durvalumab and Chemotherapy(oxaliplatin and capecitabine)
-
Beijing, Beijing, ChinaPeking Union Medical College Hospital
Oct 1, 2023
Healthy Aging, Healthy Lifestyle, Healthy Diet Trial (1. Nutrition; 2. Physical activity; 3. Hypoxic training; 4. Menthal heals
Recruiting
- Healthy Aging
- +2 more
- 1. Nutrition; 2. Physical activity; 3. Hypoxic training; 4. Menthal heals improvement
-
Saint Petersburg, Russian FederationFirst Line Health Care Resort
Oct 28, 2022
Haemophagocytic Lymphohistiocytosis Trial (Ruxolitinib)
Not yet recruiting
- Haemophagocytic Lymphohistiocytosis
- (no location specified)
Feb 28, 2023
Ampullary Carcinoma Trial (Surufatinib+Toripalimab+AG)
Not yet recruiting
- Ampullary Carcinoma
- (no location specified)
Sep 29, 2023
Colorectal Cancer Trial in Shanghai (FOLFIRI+Bevacizumab)
Recruiting
- Colorectal Cancer
-
Shanghai, Pudong, ChinaAffiliated Cancer Hospital of Fudan University
Jul 24, 2023
ASCT Versus Chemotherapy as First-Line Consolidation Therapy
Completed
- T-cell Lymphoma Adults
- consolidation with ASCT
- (no location specified)
Nov 25, 2023
Inetetamab Combined With Pyrotinib and Vinorelbine as First-line
Recruiting
- Breast Neoplasms
- Inetetamab
- +2 more
-
Nanjing, Jiangsu, ChinaJiangsu Provincial People's Hospital
Mar 16, 2023
Limited Stage Small Cell Lung Cancer, Not Progressed After First-line Chemoradiotherapy Trial in Jinan (TQB2450 Injection +
Recruiting
- Limited Stage Small Cell Lung Cancer
- Not Progressed After First-line Chemoradiotherapy
- TQB2450 Injection + Anlotinib Hydrochloride Capsules
-
Jinan, Shandong, ChinaCancer Hospital Affiliated to Shandong First Medical University
Jul 5, 2023